Comparison of Oligonucleotide Ligation Assay and Consensus Sequencing for Detection of Drug-Resistant Mutants of Human Immunodeficiency Virus Type 1 in Peripheral Blood Mononuclear Cells and Plasma
Open Access
- 1 August 2004
- journal article
- Published by American Society for Microbiology in Journal of Clinical Microbiology
- Vol. 42 (8) , 3670-3674
- https://doi.org/10.1128/jcm.42.8.3670-3674.2004
Abstract
Drug-resistant mutants of human immunodeficiency virus type 1 (HIV-1) recede below the limit of detection of most assays applied to plasma when selective pressure is altered due to changes in antiretroviral treatment (ART). Viral variants with different mutations are selected by the new ART when replication is not suppressed or wild-type variants with greater replication fitness outgrow mutants following the cessation of ART. Mutants selected by past ART appear to persist in reservoirs even when not detected in the plasma, and when conferring cross-resistance they can compromise the efficacy of novel ART. Oligonucleotide ligation assay (OLA) of virus in plasma and peripheral blood mononuclear cells (PBMC) was compared to consensus sequence dideoxynucleotide chain terminator sequencing for detection of 91 drug resistance mutations that had receded below the limit of detection by sequencing of plasma. OLA of plasma virus detected 27.5% (95% confidence interval [CI], 19 to 39%) of mutant genotypes; consensus sequencing of the PBMC amplicon from the same specimen detected 23.1% (95% CI, 14 to 34%); and OLA of PBMC detected 53.8% (95% CI, 44 to 64%). These data suggest that concentrations of drug-resistant mutants were greater in PBMC than in plasma after changes in ART and indicate that the OLA was more sensitive than consensus sequencing in detecting low levels of select drug-resistant mutants.Keywords
This publication has 31 references indexed in Scilit:
- Antiretroviral-Drug Resistance among Patients Recently Infected with HIVNew England Journal of Medicine, 2002
- Longitudinal Use of a Line Probe Assay for Human Immunodeficiency Virus Type 1 Protease Predicts Phenotypic Resistance and Clinical Progression in Patients Failing Highly Active Antiretroviral TherapyAntimicrobial Agents and Chemotherapy, 2002
- Rapid and Sensitive Oligonucleotide Ligation Assay for Detection of Mutations in Human Immunodeficiency Virus Type 1 Associated with High-Level Resistance to Protease InhibitorsJournal of Clinical Microbiology, 2002
- Underestimation of HIV Type 1 Drug Resistance Mutations: Results from the ENVA-2 Genotyping Proficiency ProgramAIDS Research and Human Retroviruses, 2002
- HIV-1 Drug Resistance Profiles in Children and Adults With Viral Load of <50 Copies/mL Receiving Combination TherapyJAMA, 2001
- Virologic and Immunologic Consequences of Discontinuing Combination Antiretroviral-Drug Therapy in HIV-Infected Patients with Detectable ViremiaNew England Journal of Medicine, 2001
- Comparison of DNA Sequencing and a Line Probe Assay for Detection of Human Immunodeficiency Virus Type 1 Drug Resistance Mutations in Patients Failing Highly Active Antiretroviral TherapyJournal of Clinical Microbiology, 2001
- A randomized study of antiretroviral management based on plasma genotypic antiretroviral resistance testing in patients failing therapyAIDS, 2000
- Antiretroviral Drug Resistance Testing in Adult HIV-1 InfectionJAMA, 2000
- Phenotypic Assays and Sequencing Are Less Sensitive Than Point Mutation Assays for Detection of Resistance in Mixed HIV-1 Genotypic PopulationsJAIDS Journal of Acquired Immune Deficiency Syndromes, 1999